PMID- 36646606
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230320
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 23
IP  - 3
DP  - 2023 Mar
TI  - CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A 
      Single-Center Retrospective Canadian Study.
PG  - 203-210
LID - S2152-2650(22)01779-7 [pii]
LID - 10.1016/j.clml.2022.12.015 [doi]
AB  - BACKGROUND: Chimeric antigen receptor (CAR) T-cells are an important new 
      third-line treatment option for large B-cell lymphoma (LBCL). The objective 
      response rates in pivotal early phase clinical trials with CAR T-cells were very 
      promising. The objective of this study was to describe the efficacy results 
      obtained with CAR T-cells infusions in our institution and to compare the 
      toxicities of our cohort with those of pivotal trials and studies conducted in a 
      real-life setting. PATIENTS AND METHODS: Efficacy and safety data were 
      retrospectively collected from 25 patients with LBCL treated with CAR T-cells 
      therapy at CHU de Quebec-Universite Laval. A literature search was then performed 
      to identify other efficacy or safety data from a real-life setting. RESULTS: At 3 
      months post infusion, the objective response rate (ORR) in our population with 
      tisagenlecleucel and axicabtagene-ciloleucel were 20% and 47%, respectively. 
      Bulky disease was the only negative predictor of poor response at 3 months (0% 
      vs. 53%, P = .03). Bulky disease was associated with a median PFS of 2 months 
      compared to 5 months for non-bulky disease (P = .0009). Grade >/= 3 hematological 
      toxicities were greater in patients treated with axi-cel (60% vs. 20%, P = .048), 
      without bone marrow involvement (55% vs. 0%, P =.046), without stage IV disease 
      (72% vs. 21%, P =.02), with refractory disease (67% vs. 10%, P =.01) or having 
      been affected by cytokine release syndrome (58% vs. 0%, P =.02). CONCLUSION: The 
      poor response rate at 3 months after infusion in our cohort was influenced mainly 
      by bulky disease. Further studies are needed to better characterize the loss of 
      efficacy of CAR T-cells because the majority of patients will relapse over time.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Benoit, Aurelie
AU  - Benoit A
AD  - Department of pharmacy, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada; 
      Faculte de pharmacie, Universite de Bordeaux, Bordeaux, Nouvelle Aquitaine, 
      France; Unite pour l'usage optimal du medicament et la recherche (UGMR), CHU de 
      Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - B Boies, Marie-Helene
AU  - B Boies MH
AD  - Department of pharmacy, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada; 
      Unite pour l'usage optimal du medicament et la recherche (UGMR), CHU de Quebec - 
      Universite Laval, Quebec, Quebec, Canada.
FAU - Dery, Nicole
AU  - Dery N
AD  - Department of pharmacy, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada; 
      Unite pour l'usage optimal du medicament et la recherche (UGMR), CHU de Quebec - 
      Universite Laval, Quebec, Quebec, Canada.
FAU - M Garcia, Luciana
AU  - M Garcia L
AD  - Department of medicine, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Simard, Melanie
AU  - Simard M
AD  - Department of pharmacy, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Poirier, Mireille
AU  - Poirier M
AD  - Department of pharmacy, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Delage, Robert
AU  - Delage R
AD  - Department of medicine, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Lortal Canguilhem, Barbara
AU  - Lortal Canguilhem B
AD  - Department of pharmacy, Institut Bergonie, Bordeaux, Nouvelle Aquitaine, France.
FAU - Doyle, Catherine
AU  - Doyle C
AD  - Department of medicine, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Larouche, Jean-Francois
AU  - Larouche JF
AD  - Department of medicine, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Couture, Felix
AU  - Couture F
AD  - Department of medicine, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada.
FAU - Lemieux, Christopher
AU  - Lemieux C
AD  - Department of medicine, CHU de Quebec - Universite Laval, Quebec, Quebec, Canada. 
      Electronic address: christopher.lemieux.med@ssss.gouv.qc.ca.
LA  - eng
PT  - Journal Article
DEP - 20221230
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - Canada
MH  - *Neoplasm Recurrence, Local/drug therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - Immunotherapy, Adoptive/methods
MH  - T-Lymphocytes
MH  - Antigens, CD19
OTO - NOTNLM
OT  - Axicabtagene ciloleucel
OT  - Cellular therapy
OT  - Efficacy
OT  - Tisagenlecleucel
OT  - Tolerance
EDAT- 2023/01/17 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/01/16 21:59
PHST- 2022/10/29 00:00 [received]
PHST- 2022/12/18 00:00 [revised]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/01/16 21:59 [entrez]
AID - S2152-2650(22)01779-7 [pii]
AID - 10.1016/j.clml.2022.12.015 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):203-210. doi: 
      10.1016/j.clml.2022.12.015. Epub 2022 Dec 30.